Comparative Pharmacology
Head-to-head clinical analysis: BREO ELLIPTA versus OTIPRIO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREO ELLIPTA versus OTIPRIO.
BREO ELLIPTA vs OTIPRIO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, leading to inhibition of DNA replication and transcription.
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
1 mg/kg intravenous infusion over 1 hour every 12 hours; typical adult dose is 100 mg every 12 hours.
None Documented
None Documented
Fluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
Mean terminal elimination half-life is approximately 4.5 hours (range 3-6 hours); prolonged in renal impairment requiring dose adjustment.
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
Primarily renal excretion of unchanged drug (approximately 80% over 24 hours) via glomerular filtration; biliary/fecal elimination accounts for <5%.
Category C
Category C
Corticosteroid/Beta-2 Agonist Combination
Otic Antibiotic/Corticosteroid